Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250475 | 0.90 | PARP1 (0.51) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL13250471 | 0.88 | C5AR1 (0.42) | SPRMAPTNAMPTPARP1TNKS2 | |
| SCHEMBL417157 | 0.86 | MAPT (0.45) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL21041448 | 0.85 | MAPT (0.44) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL31128509 | 0.84 | PARP1 (0.44) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL6220992 | 0.84 | MAPT (0.43) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL30850341 | 0.80 | SPR (0.49) | SPRNAMPTPARP1PARP15PARP3 | |
| SCHEMBL9610905 | 0.80 | MTHFD2 (0.53) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL28647996 | 0.80 | PARP1 (0.47) | SPRMAPTPARP1TNKS2PARP2 | |
| SCHEMBL31351571 | 0.79 | PARP1 (0.42) | SPRMAPTPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615441-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF | Ribometrix, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-118772141-A | DNA polymerase Theta inhibitors for the treatment of cancer | 艾立康药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118772113-A | Nitrogen-containing heterocyclic compounds as DNA polymerase Theta inhibitors | 艾立康药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024103067-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024103067-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SPR 2003/4885MAPT 3884/4885NAMPT 596/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SPR 2003/4885MAPT 3884/4885NAMPT 596/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SPR 2003/4885MAPT 3884/4885NAMPT 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.